X0206 3 2022-02-28 0 0000891293 CTI BIOPHARMA CORP CTIC 0001916577 Fong James K C/O CTI BIOPHARMA CORP. 3101 WESTERN AVENUE, SUITE 800 SEATTLE WA 98121 0 1 0 0 See Remarks Common Stock 3565 D Stock Option (right to buy) 60.50 2022-04-12 Common Stock 360 D Stock Option (right to buy) 35.70 2024-03-24 Common Stock 2430 D Stock Option (right to buy) 19.40 2025-03-17 Common Stock 3700 D Stock Option (right to buy) 4.475 2026-05-18 Common Stock 8250 D Stock Option (right to buy) 4.33 2027-03-01 Common Stock 10000 D Stock Option (right to buy) 3.19 2027-09-29 Common Stock 58750 D Stock Option (right to buy) 4.14 2028-05-16 Common Stock 23340 D Stock Option (right to buy) 0.9489 2029-02-19 Common Stock 288000 D Stock Option (right to buy) 1.00 2030-06-05 Common Stock 210000 D Stock Option (right to buy) 3.30 2031-03-10 Common Stock 115000 D Stock Option (right to buy) 3.05 2031-09-23 Common Stock 210000 D This option represents the right to purchase 360 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 2,430 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 3,700 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 8,250 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 10,000 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 58,750 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 23,340 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 288,000 shares of the Issuer's common stock and is fully vested. This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests in equal semi-annual installments beginning on September 11, 2020 through March 11, 2023, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase 115,000 shares of the Issuer's common stock and vests in approximately equal semi-annual installments beginning on September 10, 2021 through March 10, 2024, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase 210,000 shares of the Issuer's common stock and vests 25% annually beginning on February 28, 2023, subject to the Reporting Person's continued service to the Issuer. Senior Vice President and Chief Commercial Officer Exhibit 24 - Power of Attorney /s/ Bruce J. Seeley, Attorney-in-fact for James K. Fong 2022-03-11